Evidence of direct interaction between cisplatin and the caspase‐cleaved prostate apoptosis response‐4 tumor suppressor

Abstract

Prostate apoptosis response‐4 (Par‐4) tumor suppressor protein has gained attention as a potential therapeutic target owing to its unique ability to selectively induce apoptosis in cancer cells, sensitize them to chemotherapy and radiotherapy, and mitigate drug resistance. It has recently been reported that Par‐4 interacts synergistically with cisplatin, a widely used anticancer drug. However, the mechanistic details underlying this relationship remain elusive. In this investigation, we employed an array of biophysical techniques, including circular dichroism (CD) spectroscopy, dynamic light scattering (DLS), and UV‐vis absorption spectroscopy, to characterize the interaction between the active caspase‐cleaved Par‐4 fragment (cl‐Par‐4) and cisplatin. Additionally, elemental analysis was conducted to quantitatively assess the binding of cisplatin to the protein, utilizing inductively coupled plasma‐optical emission spectroscopy (ICP‐OES) and atomic absorption spectroscopy (AAS). Our findings provide evidence of direct interaction between cl‐Par‐4 and cisplatin, and reveal a binding stoichiometry of 1:1. This result provides insights that could be useful in enhancing the efficacy of cisplatin‐based and tumor‐suppressor‐based cancer therapies.This article is protected by copyright. All rights reserved.